Who Owns agilon health Company?

agilon health Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns agilon health?

The ownership structure of a company is a critical indicator of its influence, strategic direction, and accountability. A pivotal moment for agilon health, inc. (NYSE: AGL), a healthcare company focused on transforming primary care for seniors, was its Initial Public Offering (IPO) on April 15, 2021. This event marked a significant transition from its private equity-backed origins to a publicly traded entity, fundamentally reshaping its ownership landscape.

Founded in 2016 by Ronald A. Williams and Veeral Desai, with its headquarters currently in Westerville, Ohio, agilon health was established with the vision to empower primary care physicians to deliver improved outcomes and manage the health of senior patients more effectively, thereby reducing overall healthcare costs. The company provides a comprehensive platform encompassing technology, services, and capital to help physician groups transition to and succeed in value-based care models. As of July 2025, agilon health has a market capitalization of approximately $877.58 million, reflecting its position in the healthcare services sector, serving around 605,000 total members on its platform as of March 31, 2025, including 491,000 Medicare Advantage members.

Understanding who owns agilon health is key to grasping its strategic direction and the forces shaping its future. Following its IPO, the ownership of agilon health shifted significantly, moving from a concentrated private equity-backed structure to a more diversified public ownership model. This transition means that a substantial portion of the company is now held by institutional investors and individual shareholders, impacting who benefits from agilon health's success and who influences its operations.

Before its public debut, private equity firms played a substantial role in agilon health's development. However, the IPO opened the door for broader public participation, making it a publicly traded company where anyone can buy shares. This shift means that major institutional investors, such as mutual funds and hedge funds, often hold significant blocks of stock, alongside a multitude of individual investors. The agilon health ownership history shows a clear move towards public accessibility. Examining the agilon health stock ownership reveals a dynamic interplay between large institutional holders and the broader market. This evolution in agilon health's ownership structure is a critical aspect of understanding its current market position and future trajectory.

The agilon health parent company is now the public entity itself, with its shares traded on the New York Stock Exchange. The agilon health stakeholders include a wide range of entities, from its founders and executive leadership to institutional investors and individual shareholders. The agilon health board of directors ownership also plays a role, as directors often hold company stock, aligning their interests with those of other shareholders. Understanding the agilon health company ownership breakdown provides insight into the distribution of control and financial interest within the organization. The agilon health executive leadership ownership is also a key factor, as their stake can indicate their commitment to the company's long-term vision.

As a publicly traded entity, the question of who controls agilon health is largely answered by the aggregate voting power of its shareholders, with significant influence often wielded by major institutional investors in agilon health. The agilon health ownership history demonstrates a transition from private equity ownership of agilon health to a model where the public owns agilon health stock. This makes agilon health a company where a diverse group of individuals and institutions have a vested interest in its performance, including those who might utilize its services or benefit from its innovations, such as those explored in the agilon health BCG Matrix.

agilon health was established in 2016, with its official incorporation taking place in April 2017. The company's inception was significantly influenced by the private equity firm Clayton, Dubilier & Rice (CD&R). Prior to its initial public offering (IPO), an investment fund linked to CD&R held a substantial ownership stake, controlling approximately 69% of all outstanding shares. This considerable early ownership by CD&R highlighted their pivotal role in the company's foundation and their support for its initial growth trajectory.

While the precise equity distribution among co-founders Ronald A. Williams and Veeral Desai at the company's outset is not publicly disclosed, their roles as co-founders and their continued involvement are notable. Ron Williams serves as co-founder and Chairman of the Board, and Ravi Sachdev, a partner at CD&R, is also recognized as a founder, underscoring their integral part in shaping the company's strategic direction and early governance. The founding team's vision was centered on revolutionizing healthcare by equipping primary care physicians with a value-based Total Care Model. This vision was intrinsically linked to the early ownership structure, which utilized private equity capital to build the necessary infrastructure and forge partnerships before seeking public investment.

Founding Year

agilon health was founded in 2016, with its legal incorporation in April 2017.

Key Private Equity Backer

The company's formation was significantly driven by the private equity firm Clayton, Dubilier & Rice (CD&R).

Pre-IPO Ownership by CD&R

An investment fund associated with CD&R held approximately 69% of all shares before the IPO.

Co-Founders

Ronald A. Williams and Veeral Desai are recognized as co-founders, with Ron Williams also serving as Chairman of the Board.

CD&R Partner as Founder

Ravi Sachdev, a CD&R partner, is also listed as a founder, reflecting CD&R's deep involvement.

Early Financial Backers

Other early investors included venture capital and private equity firms like Oak HC/FT, Summit Partners, and Sequoia Capital.

Founding Vision and Control

The founding team's core objective was to transform healthcare by empowering primary care physicians through a value-based Total Care Model. This foundational vision was closely tied to the early distribution of control, leveraging private equity capital to establish the necessary infrastructure and partnerships before transitioning to public investment. Understanding this early ownership structure is key to understanding the Growth Strategy of agilon health.

• The company's strategy was built around a value-based Total Care Model.
• Private equity funding was crucial for early infrastructure and partnerships.
• The initial ownership structure reflected the significant role of private equity.
• The founders aimed to empower primary care physicians.

agilon health SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership journey of agilon health saw a significant transformation with its initial public offering (IPO) on April 15, 2021. This event marked its transition from a company largely influenced by private equity to one accessible to public market investors. The IPO was priced at $23 per share, successfully raising approximately $1.07 billion and establishing an initial market capitalization of roughly $8.85 billion. This public debut fundamentally altered the landscape of who owns agilon health.

As of July 18, 2025, the market capitalization has adjusted to approximately $877.58 million. The current agilon health ownership structure is heavily dominated by institutional investors, who held about 97.36% of the company's shares as of March 31, 2025. Among these major institutional investors, Clayton, Dubilier & Rice, LLC held a substantial 24.25%, Capital World Investors had 12.95%, and Morgan Stanley Investment Management, Inc. owned 12.62%, also as of March 31, 2025. Other significant stakeholders include Vanguard Group Inc, BlackRock, Inc., and Fmr Llc. Retail investors collectively own approximately 46.29% of the shares, while company insiders hold about 2.23% as of July 2025. This concentration of institutional ownership, particularly by Clayton, Dubilier & Rice, LLC, suggests their continued significant role in shaping agilon health's strategic direction and corporate governance, even after becoming a publicly traded entity. The investment landscape is dynamic, as evidenced by a 3.80% decrease in total shares held by institutions in the three months preceding April 8, 2025, and an increase in holdings by funds like SMCWX - SMALLCAP WORLD FUND INC, indicating shifts in investor sentiment and strategy that can impact the company's stock performance.

Understanding agilon health's ownership structure reveals a strong institutional presence, with Clayton, Dubilier & Rice, LLC being a key player since the company's public offering. This ownership breakdown highlights the influence of large investment firms on the company's trajectory.

Key Aspects of agilon health's Ownership

The ownership of agilon health is primarily held by institutional investors, reflecting a significant shift since its IPO. This concentration of ownership influences strategic decisions and market perception.

• agilon health is a publicly traded company listed on the NYSE.
• Institutional investors hold the vast majority of shares.
• Clayton, Dubilier & Rice, LLC is a major stakeholder.
• The company's market capitalization has seen fluctuations since its IPO.
• Understanding these stakeholders is crucial for assessing the company's future direction, similar to how one might analyze the Marketing Strategy of agilon health.

agilon health PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of May 2025, agilon health's governance is overseen by a Board of Directors comprising eight members, with a clear emphasis on independence, as a majority of these directors are independent. This board structure reflects a blend of individuals with foundational ties to the company, representatives from significant investment entities, and independent directors bringing diverse expertise. Key figures on the board include Ron Williams, who serves as co-founder and Chairman of the Board, and Ravi Sachdev, another co-founder and a partner at Clayton, Dubilier & Rice (CD&R). The current Chief Executive Officer, Steve Sell, also holds a position as a director. The board is further comprised of Silvana Battaglia, Sharad Mansukani, M.D., Diana L. McKenzie, Karen McLoughlin, and William Wulf, M.D. Notably, Dr. Wulf also leads Central Ohio Primary Care, a significant physician group partner of agilon health.

The voting power within agilon health is structured around a one-share-one-vote principle, a common framework for publicly traded corporations, with no disclosed dual-class share structures or preferential voting rights for any specific individuals or entities in recent filings. The company employs a classified board system, where directors serve in staggered three-year terms. While precise voting power percentages for individual board members are not publicly detailed, the substantial institutional ownership, particularly from CD&R, indicates their considerable influence through board representation and their participation in corporate decision-making. Routine governance activities, such as the approval of auditors and advisory votes on executive compensation, are standard procedures. For instance, at the 2024 annual meeting, approximately 82.8% of votes were cast in favor of executive compensation. There have been no significant proxy battles or activist investor campaigns that have notably altered the company's strategic direction in recent years, suggesting a stable governance environment.

The ownership structure of agilon health is characterized by a one-share-one-vote system, which is standard for publicly traded companies. This means that each share of common stock typically carries one vote. While specific ownership percentages for individual board members are not disclosed, the presence of significant institutional investors, such as Clayton, Dubilier & Rice (CD&R), through their board representation and shareholdings, suggests a substantial level of influence on corporate matters. Understanding who owns agilon health involves looking at these major institutional investors and the broader public float. The company's history, as detailed in the Brief History of agilon health, provides context for its current ownership landscape.

Understanding agilon health's Ownership and Governance

agilon health operates with a board structure designed for effective oversight. The company's voting power is distributed through a standard one-share-one-vote mechanism.

• Majority of directors are independent.
• Key shareholders, like CD&R, have board representation.
• Staggered three-year terms for board members.
• No disclosed dual-class share structures.

agilon health Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership landscape of agilon health has seen considerable shifts, reflecting both market dynamics and internal strategic adjustments. The company's market capitalization has experienced a significant downturn, decreasing from $8.85 billion at its Initial Public Offering to approximately $877.58 million as of July 2025. This represents a substantial decline of over 90%, influenced by broader economic conditions and specific business decisions, including the exit from certain market partnerships and payer contracts affecting around 54,000 members for the entirety of 2025.

Leadership changes have also been a notable trend, with key appointments made to strengthen the company's operational and financial oversight. Jeff Schwaneke joined as Chief Financial Officer and Executive Vice President on July 1, 2024, taking over from Timothy Bensley. Additionally, Dr. Karthik Rao was appointed Chief Medical Officer and Dr. Kevin Spencer became Chief Clinical Officer in 2024. These personnel moves underscore a commitment to robust financial management and strategic development.

The ownership structure shows a strong institutional presence, with institutions holding approximately 97.36% of shares as of March 31, 2025. However, this segment saw a slight decrease of 3.80% in total institutional shares in the three months prior to April 8, 2025. Insider ownership is reported at about 2.23% as of July 2025, with some directors engaging in buying activity in late 2024. The company is actively working to reduce underwriting risks and enhance its platform capabilities, aiming for sustained growth despite market exits and the challenging Medicare Advantage environment. Agilon health has maintained its full-year 2025 revenue projections, anticipating between $5.85 billion and $6.025 billion, and expects to reach break-even cash flow by 2027, supported by its capital-light approach and strategic initiatives. Understanding Revenue Streams & Business Model of agilon health is key to grasping the company's financial trajectory and ownership value.

Institutional Investor Dominance

Institutions represent the vast majority of agilon health's ownership, holding nearly 97.36% of shares as of March 31, 2025. This indicates significant confidence from large financial entities in the company's long-term strategy.

Insider Activity and Confidence

Insider ownership stands at approximately 2.23% as of July 2025. The observed insider buying in late 2024 by directors suggests a belief in the company's future prospects among those with intimate knowledge of its operations.

Market Capitalization Trends

The company's market capitalization has seen a dramatic decrease since its IPO, falling by over 90% to around $877.58 million by July 2025. This trend reflects broader market challenges and company-specific strategic adjustments.

Strategic Evolution and Financial Outlook

Agilon health is focusing on reducing underwriting risks and refining its platform. The company reaffirmed its 2025 revenue guidance and anticipates achieving break-even cash flow by 2027, signaling a path toward financial stability.

agilon health Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔